The ProHear Study found that the drug candidate Bimokalner produced a clinically meaningful reduction in pure-tone audiometry threshold shifts in testicular cancer patients who developed cisplatin-induced ototoxicity. Acousia Therapeutics GmbH , a clinical-stage biotechnology company based in Tübingen, Germany, has announced positive top-line efficacy results from its completed Phase 2a ProHear Study , evaluating...
Phase 2a results are encouraging but insufficient to change current practice; clinicians should monitor for a Phase 3 trial before considering Bimokalner as a standard protective agent against cisplatin-induced hearing loss.
Cisplatin-induced ototoxicity (medication-related hearing damage) is a significant and often permanent side effect with no approved preventive drug; a successful Phase 2a signals a potential first-in-class otoprotective therapy.
- 01Phase 2a ProHear Study evaluated Bimokalner in testicular cancer patients receiving cisplatin chemotherapy.
- 02Bimokalner produced a clinically meaningful reduction in pure-tone audiometry threshold shifts.
- 03Cisplatin-induced ototoxicity currently has no approved pharmacological prevention.
- 04Phase 2a results are reported as positive by the sponsor, Acousia Therapeutics.
- 05Larger Phase 3 trials will be needed to confirm efficacy and safety before clinical adoption.
Bimokalner produced a clinically meaningful reduction in pure-tone audiometry threshold shifts in testicular cancer patients with cisplatin-induced ototoxicity.
studypartially supported- Publication type
- clinical_trial
- Evidence level
- 1b
- Population
- Testicular cancer patients receiving cisplatin chemotherapy with cisplatin-induced ototoxicity
- Intervention
- Bimokalner (otoprotective drug candidate)
Primary outcomes
Pure-tone audiometry threshold shift reduction